Trial site
Busan
- 13running trials
- 7closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Conditions
- Acute lymphoblastic leukaemia2 trials
- Asthma2 trials
- Childhood cancers2 trials
- Chronic myeloid leukaemia2 trials
- Coronary artery disease2 trials
- Familial hypercholesterolaemia2 trials
- IgA nephropathy2 trials
- Macular degeneration2 trials
- Myeloproliferative neoplasms2 trials
- Stroke2 trials
- Ankylosing spondylitis1 trial
- Chronic kidney disease1 trial
- and 7 more
- Phase
- Phase 311 trials
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Completed7 trials
- Recruiting6 trials
- Lead sponsor
- Novartis Pharmaceuticals20 trials
Running trials
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Active, not recruiting
Recruiting
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
Recruiting
Recruiting
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
Active, not recruiting
Active, not recruiting
Recruiting
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Acute lymphoblastic leukaemia1 recruiting
- Ankylosing spondylitis1 recruiting
- Childhood cancers1 recruiting
- Diffuse large B-cell lymphoma1 recruiting
- Familial hypercholesterolaemia1 recruiting
- Follicular lymphoma1 recruiting
- Lung cancer1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Prostate cancer1 recruiting
Closed trials
Completed
Recruiting
Completed
Regulatory Post-Marketing Surveillance Study for Brolucizumab
Completed
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Completed
Completed
Completed
Site data: ClinicalTrials.govUpdated 15 Nov 2026